Gaudium IVF September revenue reaches ₹37.41 crore, profit ₹9.41 crore

Gaudium IVF and Women Health Limited reported consolidated revenue from operations of ₹37.41 crore and profit for the period of ₹9.41 crore for the quarter ended September 30, 2026, versus ₹19.38 crore and ₹1.78 crore respectively in the June 2026 quarter. Revenue was also above the ₹31.73 crore reported a year earlier.

How did Gaudium IVF's September-quarter revenue and profit change?

Gaudium IVF's revenue from operations rose ₹18.03 crore sequentially to ₹37.41 crore in the September 2026 quarter, while total income increased to ₹38.50 crore from ₹20.50 crore in the June quarter. Revenue was ₹5.68 crore higher than the ₹31.73 crore recorded in the quarter ended September 30, 2025, and total income exceeded the prior-year figure of ₹31.88 crore.

Profit before tax was ₹12.62 crore, compared with ₹2.45 crore in June 2026 and ₹12.79 crore a year earlier. Tax expense rose to ₹3.21 crore from ₹67.39 lakh in June, leaving profit for the period at ₹9.41 crore, up ₹7.64 crore sequentially and ₹3 lakh above ₹9.38 crore in the September 2025 quarter.

For the half year ended September 30, 2026, Gaudium IVF reported revenue from operations of ₹56.79 crore, compared with ₹49.50 crore in the corresponding 2025 period. Half-year profit was ₹11.19 crore, below ₹12.51 crore a year earlier, reflecting the ₹1.78 crore profit recorded in the June 2026 quarter. The group reports one operating segment, healthcare business, under Indian Accounting Standard 108.

What costs changed in Gaudium IVF's September quarter?

Gaudium IVF's total expenses increased to ₹25.88 crore in the September 2026 quarter from ₹18.05 crore in June, while revenue increased by ₹18.03 crore over the same period. Cost of rendering services rose to ₹6.08 crore from ₹1.06 crore, and purchases of drugs and medical consumables were ₹7.19 crore against ₹7.07 crore in June and ₹9.87 crore a year earlier.

Other expenses were ₹7.43 crore, compared with ₹7.33 crore in June and ₹4.26 crore in September 2025. Sales and marketing expense declined to ₹3.46 crore from ₹4.04 crore, rent fell to ₹48 lakh from ₹72 lakh, and legal and professional fees were ₹1.48 crore versus ₹1.47 crore. Employee benefit expense was ₹2.05 crore, compared with ₹2.28 crore in June.

Depreciation and amortisation rose to ₹1.41 crore from ₹72 lakh in June, while finance costs increased to ₹52 lakh from ₹38 lakh. Other income was ₹1.09 crore, including ₹97.29 lakh of interest on fixed deposits, compared with other income of ₹1.12 crore in the preceding quarter. These figures contributed to the increase in profit before tax from ₹2.45 crore to ₹12.62 crore.

What do Gaudium IVF's cash flow and balance sheet show?

Gaudium IVF generated net cash flow from operating activities of ₹19.77 crore in the half year ended September 30, 2026, compared with ₹2.36 crore in the corresponding 2025 period. Cash generated from operations was ₹20.55 crore, supported by an ₹8.28 crore reduction in trade receivables and a ₹2.66 crore reduction in other financial assets, partly offset by a ₹4.90 crore fall in trade payables.

Investing activities generated ₹15.06 crore of net cash, compared with an outflow of ₹5.44 crore a year earlier, including ₹40.28 crore from net redemption of bank deposits. This was partly offset by ₹22.34 crore of capital advances and ₹4.89 crore spent on property, plant, equipment and intangible assets. Financing activities used ₹23.13 crore, including ₹18.28 crore of net short-term borrowing repayments and ₹3.69 crore of lease-principal repayments.

Cash and cash equivalents rose to ₹20.49 crore at September 30, 2026 from ₹8.79 crore at March 31, 2026. Total assets increased to ₹200.42 crore from ₹193.10 crore, while total equity rose to ₹163.15 crore from ₹152.30 crore. Current borrowings declined to ₹4.80 crore from ₹23.07 crore, although non-current lease liabilities increased to ₹15.29 crore from ₹1.28 crore and right-of-use assets rose to ₹20.51 crore from ₹1.22 crore.

How is Gaudium IVF using IPO proceeds for expansion?

Gaudium IVF had utilised ₹50.65 crore of gross fresh-issue proceeds of ₹90.00 crore as at September 30, 2026, leaving ₹39.35 crore unutilised before interest. Including ₹53.15 lakh of net interest earned on fixed deposits, total unutilised proceeds were ₹39.88 crore. The company stated that the proceeds had been used for the purposes set out in its offer document.

Of the ₹50.00 crore allocated to capital expenditure for new in-vitro fertilisation centres, Gaudium IVF had used ₹13.48 crore by September 30, leaving ₹36.52 crore. It spent ₹12.46 crore on this purpose during the September quarter, after cumulative spending of ₹1.03 crore through June 30. The revised ₹18.07 crore allocation for debt repayment was fully utilised by June 30, while ₹11.37 crore of the ₹14.21 crore general-corporate-purpose allocation had been used.

Gaudium IVF has proposed substituting six of the 19 locations planned for new centres without changing the ₹50.00 crore expansion allocation. Its disclosed indicative plan is to establish 10 centres in fiscal 2027, eight in fiscal 2028 and one in fiscal 2029, completing all 19 by March 31, 2029. The filing says the opening sequence may differ from that schedule depending on feasibility.

Conclusion

Gaudium IVF's September quarter brought revenue to ₹37.41 crore from ₹19.38 crore in June and lifted profit to ₹9.41 crore from ₹1.78 crore. The half-year picture was more mixed, with revenue rising to ₹56.79 crore but profit declining to ₹11.19 crore from ₹12.51 crore a year earlier, alongside operating cash flow of ₹19.77 crore.

The next disclosed milestone is deployment of the ₹36.52 crore remaining for new-centre capital expenditure at September 30, 2026. Gaudium IVF's plan calls for 10 centre establishments in fiscal 2027 and completion of all 19 by fiscal 2029, while total unutilised IPO proceeds, including net fixed-deposit interest, stood at ₹39.88 crore.